---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| AAP | Abiraterone acetate plus prednisone |
| ABI | Abiraterone |
| ADT | Androgen deprivation therapy |
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| AML | Acute myeloid leukemia |
| APC | Ambulatory payment classification |
| AR | Androgen receptor |
| AR-V7 | Androgen receptor splice variant 7 |
| ARPI | Androgen receptor pathway inhibitor |
| ARTA | Androgen receptor-targeted agent |
| ASP | Average sales price |
| ATM | Ataxia-telangiectasia mutated gene |
| AUC | Area under the concentration-time curve |
| AWP | Average wholesale price |
| BC | Breast cancer |
| BCR | Biochemical recurrence |
| BCRP | Breast cancer resistance protein |
| BICR | Blinded independent central review |
| BID | Twice daily |
| BPA | Bone-protecting agent |
| BPI-SF | Brief Pain Inventory-Short Form |
| BRCA | Breast cancer susceptibility gene |
| cfDNA | Cell-free DNA |
| CI | Confidence interval |
| CMS | Centers for Medicare & Medicaid Services |
| CNS | Central nervous system |
| CR | Complete response |
| crPFS | Clinical or radiographic progression-free survival |
| CRPC | Castration-resistant prostate cancer |
| CSPC | Castration-sensitive prostate cancer |
| CT | Computed tomography |
| CTBS | Computed tomography plus bone scan |
| CTCAE | Common Terminology Criteria for Adverse Events |
| ctDNA | Circulating tumor DNA |
| CY | Calendar year |
| CYP | Cytochrome P450 |
| DDI | Drug-drug interaction |
| dMMR | Deficient mismatch repair |
| DNA | Deoxyribonucleic acid |
| DOR | Duration of response |
| EAU | European Association of Urology |
| ECG | Electrocardiogram |
| ECOG | Eastern Cooperative Oncology Group |
| eCQM | Electronic clinical quality measure |
| EED | Embryonic ectoderm development |
| eGFR | Estimated glomerular filtration rate |
| EMA | European Medicines Agency |
| ENZ | Enzalutamide |
| EOM | Enhancing Oncology Model |
| EQ-5D-5L | EuroQol five-dimension, five-level instrument |
| ER | Emergency room |
| EU | European Union |
| EZH1 | Enhancer of zeste homolog 1 |
| EZH2 | Enhancer of zeste homolog 2 |
| FACT-P | Functional Assessment of Cancer Therapy-Prostate |
| FDA | Food and Drug Administration |
| FDR | First-degree relative |
| GI | Gastrointestinal |
| GLP | Good Laboratory Practice |
| GnRH | Gonadotropin-releasing hormone |
| H3K27me3 | Histone 3 lysine 27 trimethylation |
| HCPCS | Healthcare Common Procedure Coding System |
| HCRU | Healthcare resource utilization |
| HR | Hazard ratio |
| HRQoL | Health-related quality of life |
| HRR | Homologous recombination repair |
| HRU | Healthcare resource utilization |
| ibPFS | Imaging-based progression-free survival |
| IC50 | Half-maximal inhibitory concentration |
| ICER | Incremental cost-effectiveness ratio |
| ICU | Intensive care unit |
| IND | Investigational new drug application |
| INN | International nonproprietary name |
| IQR | Interquartile range |
| IU | International unit |
| IV | Intravenous |
| LC | Lung cancer |
| LN | Lymph node |
| LOT | Line of therapy |
| MAC | Medicare Administrative Contractor |
| mCRPC | Metastatic castration-resistant prostate cancer |
| mCSPC | Metastatic castration-sensitive prostate cancer |
| MDS | Myelodysplastic syndrome |
| MFP | Maximum fair price |
| mHSPC | Metastatic hormone-sensitive prostate cancer |
| MIPS | Merit-based Incentive Payment System |
| MMR | Mismatch repair |
| mPCa | Metastatic prostate cancer |
| MR | Molecular response |
| MR50 | Molecular response of at least 50% reduction in ctDNA fraction |
| MR90 | Molecular response of at least 90% reduction in ctDNA fraction |
| MRI | Magnetic resonance imaging |
| MSI-H | Microsatellite instability-high |
| NCI | National Cancer Institute |
| NDC | National Drug Code |
| NE | Not estimable; neuroendocrine (by context) |
| NGS | Next-generation sequencing |
| NHT | Novel hormonal therapy |
| nmCRPC | Nonmetastatic castration-resistant prostate cancer |
| NR | Not reached |
| NSCLC | Non-small-cell lung cancer |
| OOP | Out-of-pocket |
| ORR | Objective response rate |
| OS | Overall survival |
| PARP | Poly(ADP-ribose) polymerase |
| PBMC | Peripheral blood mononuclear cell |
| PC | Prostate cancer |
| PCa | Prostate cancer |
| PCWG3 | Prostate Cancer Clinical Trials Working Group 3 |
| PD-1 | Programmed cell death protein 1 |
| PD-L1 | Programmed death ligand 1 |
| PET | Positron emission tomography |
| PFS | Progression-free survival |
| PK | Pharmacokinetics |
| PMPM | Per member per month |
| PO | Oral administration |
| PPPM | Per patient per month |
| PPPY | Per patient per year |
| PR | Partial response |
| PRC2 | Polycomb repressive complex 2 |
| PRO-CTCAE | Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events |
| PS | Performance status |
| PSA | Prostate-specific antigen |
| PSA50 | Decline in PSA of at least 50% from baseline |
| PSA90 | Decline in PSA of at least 90% from baseline |
| PSMA | Prostate-specific membrane antigen |
| QALY | Quality-adjusted life-year |
| QD | Once daily |
| RAD | Radiographic progression |
| RCT | Randomized controlled trial |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| RLT | Radioligand therapy |
| RP2D | Recommended phase 2 dose |
| RP3D | Recommended phase 3 dose |
| rPFS | Radiographic progression-free survival |
| RW | Real-world |
| SAE | Serious adverse event |
| SD | Standard deviation |
| SEC | Securities and Exchange Commission |
| SEER | Surveillance, Epidemiology, and End Results Program |
| SoC | Standard of care |
| SPM | Second primary malignancy |
| SRE | Skeletal-related event |
| SSE | Symptomatic skeletal event |
| TEAE | Treatment-emergent adverse event |
| TGI | Tumor growth inhibition |
| TMB-H | Tumor mutational burden-high |
| TRAE | Treatment-related adverse event |
| TTPD | Time to prostate-specific antigen progression or death |
| UCP | Unequivocal clinical progression |
| UI | Uncertainty interval |
| USD | United States dollars |
| VAS | Visual analog scale |
| WAC | Wholesale acquisition cost |
| WHO | World Health Organization |
| WTP | Willingness to pay |

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
